CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
Kosovec, Juliann E., Zaidi, Ali H., Omstead, Ashten N., Matsui, Daisuke, Biedka, Mark J., Cox, Erin J., Campbell, Patrick T., Biederman, Robert W.W., Kelly, Ronan J., Jobe, Blair A.Volume:
8
Language:
english
Journal:
Oncotarget
DOI:
10.18632/oncotarget.22244
Date:
November, 2017
File:
PDF, 3.09 MB
english, 2017